As previously disclosed, on October 1, 2020, AMAG Pharmaceuticals, Inc. (‘AMAG’), entered into an Agreement and Plan of Merger (the ‘Merger Agreement’) with Covis Group S.à r.l. (‘Covis’), Covis Mergerco Inc. and an indirect wholly owned subsidiary of Covis (‘Merger Sub’), and solely with respect to certain sections therein, Covis Finco S.à r.l. (‘Covis Finco’). Immediately upon the Merger, Michael Porter assumed the role of Chief Executive Officer of AMAG.